Kåre Engkilde

Title: Kåre Engkilde: Innovator in Immunomodulation

Introduction

Kåre Engkilde is a notable inventor based in Værløse, Denmark. He has made significant contributions to the field of immunology, particularly through his innovative research involving amniotic fluid mesenchymal stem cells. His work focuses on methods to modulate immune responses, which has potential implications for various medical applications.

Latest Patents

Kåre Engkilde holds a patent titled "Immunomodulation by amniotic fluid mesenchymal stem cells." This patent outlines methods for reducing T cell activation, including co-culturing with T cells and utilizing term amniotic fluid mesenchymal stem cells (TAF-MSCs) isolated from term human amniotic fluid. Additionally, the patent describes methods for inhibiting macrophage polarization toward the M1 pro-inflammatory phenotype through co-culturing with macrophages. Other aspects of the patent include methods for inhibiting cytokine secretion from activated Peripheral Blood Mononuclear Cells (PBMC) and differentiating TAF-MSCs.

Career Highlights

Kåre Engkilde is associated with Amniotics AB, a company that focuses on developing innovative therapies based on stem cell technology. His work at Amniotics AB has positioned him as a key player in the field of regenerative medicine. His research has the potential to lead to breakthroughs in treating various inflammatory conditions.

Collaborations

Kåre Engkilde collaborates with esteemed colleagues such as Jan Talts and Niels-Bjarne Woods. These collaborations enhance the research and development efforts at Amniotics AB, fostering an environment of innovation and scientific advancement.

Conclusion

Kåre Engkilde's contributions to immunomodulation through his patent and work at Amniotics AB highlight his role as an influential inventor in the field of stem cell research. His innovative approaches may pave the way for new therapeutic strategies in immunology.